FDA 483 - ten23 health Valais AG - August 27, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Valais AG, a drug product manufacturer in Visp, Switzerland, was cited for significant deficiencies in its manufacturing processes. The inspection revealed failures in establishing robust production controls, ensuring sterility through adequate visual inspection and aseptic procedures, and maintaining proper component testing and environmental sanitization programs. These issues collectively indicate a lack of assurance regarding the quality, purity, and sterility of their drug products.
ID · 83145e5a-a987-4b0c-b84f-5a2b02733371